Egle Therapeutics Secures €9.3 Million from France 2030 Initiative
Deal News | Mar 17, 2025 | Bioqube Ventures NV
Egle Therapeutics, a biotech company focusing on immunotherapies for cancer and autoimmune diseases, has announced receipt of €9.3 million in funding under the 'Innovations in Biotherapies and Bioproduction' call, part of France's ambitious France 2030 plan. This state funding, managed by Bpifrance, aims to accelerate the clinical development of Egle's lead drug, EGL-001, which is currently in Phase I/II trials. Founded as a spinoff from Institut Curie in 2020, Egle is recognized for its work on targeting regulatory T cells. The company has previously raised substantial capital, including €47 million in a Series A round in 2021, with notable investors such as EQT Life Sciences and Bpifrance. The France 2030 initiative, a massive €54 billion investment project, seeks to position France as a leader in innovation by supporting key economic sectors, including healthcare. Egle's funding aligns with its strategic objectives to advance novel therapeutic candidates. The firm's latest appointments and technological progress mark significant milestones as it prepares further clinical trials.
Sectors
- Biotechnology
- Healthcare
Geography
- France – France is central to this article as it is the location of Egle Therapeutics, where the state funding is applied, and is the focus of the France 2030 initiative.
Industry
- Biotechnology – Egle Therapeutics operates within the biotechnology industry as it develops immunotherapies targeting regulatory T cells for potential treatment of cancer and autoimmune diseases.
- Healthcare – The funding from France 2030 is targeted at advancing healthcare innovations through biotherapies, directly impacting Egle Therapeutics' efforts in developing clinical-stage therapies.
Financials
- €9.3 million – State funding received by Egle Therapeutics under the Innovations in Biotherapies and Bioproduction call for projects.
- €47 million – Amount raised by Egle Therapeutics in its Series A financing round.
- €56 million – Total funds raised by Egle Therapeutics through equity financing and non-dilutive public funding since inception.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Egle Therapeutics | Target | Company | A biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. |
| Bioqube Ventures NV | Private Equity Firm | Company | A private equity firm involved in the Series A financing of Egle Therapeutics. |
| Bpifrance | Government | Agency | Manages the state funding for France 2030 initiative and supports business innovation and international expansion. |
| Takeda Pharmaceuticals | Other Companies | Company | Has a strategic partnership with Egle Therapeutics, supporting research and development through collaboration and funding. |
| Christophe Quva | CEO | Person | CEO of Egle Therapeutics overseeing the company's strategic direction and operations. |